New York, NY, United States of America

Emma Guttman

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Anaptysbio, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emma Guttman: Innovator in Dermatological Treatments

Introduction

Emma Guttman is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of dermatology, particularly in the treatment of skin conditions. Her innovative approach has led to the development of a unique patent that addresses a specific medical need.

Latest Patents

Emma Guttman holds a patent titled "Method of Treating Ichthyosis in a Subject by Administering an Anti-Interleukin 36 Receptor (IL-36R) Binding Agent." This patent represents her commitment to advancing medical treatments and improving patient outcomes. She has 1 patent to her name, showcasing her dedication to innovation in healthcare.

Career Highlights

Emma is currently associated with Anaptysbio, Inc., where she continues to work on groundbreaking research and development projects. Her role at the company allows her to collaborate with other talented professionals in the field, further enhancing her contributions to dermatological science.

Collaborations

Emma has worked alongside notable colleagues such as Marco Londei and Rupal Kalapanda. These collaborations have fostered a dynamic environment for innovation and have led to advancements in their shared field of expertise.

Conclusion

Emma Guttman is a trailblazer in the realm of dermatological treatments, with her innovative patent reflecting her commitment to improving patient care. Her work at Anaptysbio, Inc. and collaborations with esteemed colleagues further underscore her impact in the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…